Seven hypertriglyceridemic patients with type-2 diabetes were treated with atorvastatin (40 mg/day) for 2 months. Kinetics of apolipoprotein B100 (apoB100)-containing lipoproteins were determined before and after atorvastatin treatment and compared with data obtained in five normolipidemic volunteers. ApoB100 metabolism was studied using stable isotopes and multicompartmental modeling. Compared with normolipidemic obese subjects, type-2 diabetic patients had a higher apoB100 concentration in very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and low-density lipoproteins (LDL) (P Ͻ 0.005). Kinetic analysis showed an increase in the total apoB100 production rate (P Ͻ 0.005) related to VLDL apoB100 overproduction (P Ͻ 0.005). Patients were also characterized by a lower fractional catabolic rate (FCR) in VLDL (not significant) or IDL (P Ͻ 0.005) mainly related to a decrease in VLDL and IDL delipidation rate (P Ͻ 0.005). Catabolism of LDL was also lower in diabetic patients (P Ͻ 0.05). Atorvastatin treatment significantly decreased plasma triglycerides (P Ͻ 0.05), total and LDL cholesterol (P Ͻ 0.05), apoB100 in LDL, IDL, and VLDL (P Ͻ 0.05). Treatment significantly decreased total apoB100 production rate (P Ͻ 0.05), but only for VLDL (P Ͻ 0.05). Treatment normalized FCR in IDL and LDL (P Ͻ 0.05). We concluded that atorvastatin improved lipid abnormalities in type-2 diabetic patients not only by increasing the clearance of apoB100-containing lipoproteins but also by decreasing VLDL production.
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Atherosclerosis is the leading cause of morbidity and mortality in type-2 diabetic patients. Hypertriglyceridemia is an important lipid disorder associated with type-2 diabetes and may contribute to the development of atherosclerosis (Goldberg, 2001 ). Results of studies showing possible disturbances in LDL metabolism are inconsistent (Howard, 1987) . Previous studies have underlined that the insulin resistance observed in type-2 diabetes is associated with an overproduction of apoB100 containing lipoproteins and reduced LDL and VLDL catabolism .
Atorvastatin is a strong competitive inhibitor of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase. In patients with familial hypercholesterolemia and combined hyperlipidemia, the cholesterol-lowering effects are related to reduction of LDL cholesterol and are explained either by an increase in LDL receptor activity or by reduction of LDL apoB100 production with atorvastatin, as observed with other statins (Aguilar-Salinas et al., 1998) . In addition to its cholesterollowering effect, atorvastatin also shows significant triglyceride-lowering properties in hypertriglyceridemic subjects (Lea and McTavish, 1997) , but conflicting results were reported concerning its effect on VLDL metabolism. Various effect have been already reported on VLDL production with atorvastatin: inhibiting effect in animal or cell models , stimulating effect (Forster et al., 1996) or no effect (Forster et al., 2002) in combined hyperlipidemic subjects, and no effect in insulin resistant patients with no diabetes mellitus (Chan et al., 2002 ). It appears, however, that statins could have an effect on VLDL production in situations with high VLDL production (Aguilar-Salinas et al., 1998) .
The aim of the present study was to evaluate metabolic changes induced by atorvastatin in patients with type-2 diabetes and marked hypertriglyceridemia. This study focuses on the apoB100-containing lipoproteins (VLDL, IDL, and LDL) in diabetic patients with combined dyslipidemia. We have studied apoB100 metabolism using endogenous labeling with deuterated leucine and multicompartmental modeling to analyze lipoprotein kinetics before and after atorvastatin treatment.
Materials and Methods

Subjects
Seven patients with type-2 diabetes and dyslipidemia (Table 1) were included in the study. Insulin treatment was an exclusion criterion. Patients were treated with either sulfamides or biguanides for at least 3 months, and no treatment change was allowed for the duration of the study. The insulin resistance was assessed by insulin sensitivity index (homeostasis model assessment; HOMA) (Matthews et al., 1985) . Five normolipidemic obese subjects matched for age and body mass index with the diabetic patients were also studied as controls. The study subjects were instructed by a dietician to follow a weight-maintenance diet composed of 45% carbohydrate, 35% fat, and 20% protein for at least 1 week before study commencement. The experimental protocol was approved by the ethical committee of Nantes University Hospital, and written informed consent was obtained before the study was started.
Experimental Protocol Diabetic patients were treated for 2 months with atorvastatin (40 mg/day). Kinetic studies of apoB100 metabolism were performed before and after treatment. The endogenous labeling of apoB100 was carried out by constant infusion of [D 3 ]leucine in subjects fasted overnight for 12 h before the study and who continued fasting during the entire procedure (Maugeais et al., 2001) .
Each subject received intravenously a prime of 10 mol ⅐ kg Ϫ1 of tracer immediately followed by a constant tracer infusion (10 mol ⅐ kg Ϫ1 ⅐ h
Ϫ1
) for 14 h. Venous blood samples were drawn into EDTA tubes (Venoject, Paris, France) at baseline and at 15, 30, 45 min, at 1, 1.5, 2, and 2.5 h, and then hourly until 14 h. Sodium azide, an inhibitor of bacterial growth, and Pefabloc SC (Interchim, Montluçon, France), a protease inhibitor, were added to blood samples at a final concentration of 1.5 and 0.5 mM, respectively.
Analytical Procedures
Isolation and Measurement of Enrichment of Lipoprotein Containing apoB100. VLDL1 (Svedbery flotation rate 400 -60) and VLDL2 (Svedbery flotation rate 60 -20) were separated by density gradient ultracentrifugation (Gaw et al., 1992 ) using a swinging bucket rotor at 40,000 revolutions/min for 24 h at 10°C (RPS 40T; Hitachi, Hialeah, FL). IDL (1.006 Ͻ density Ͻ 1.020 g/ml) and LDL (1.020 Ͻ density Ͻ 1.063 g/ml) were separated by standard sequential ultracentrifugation methods (Havel et al., 1955 ) using a fixedangle rotor at 40,000 revolutions/min for 22 h at 10°C (CP70; Hitachi).
Isolation and measurement of leucine enrichment in apoB100 have been described previously (Maugeais et al., 2001) . Briefly, apoB100 in lipoproteins was isolated by SDS-polyacrylamide gel electrophoresis. Apolipoprotein bands were dried under a vacuum and then hydrolyzed. The amino acids were purified by cation exchange chromatography, then esterified, and derivatized. Electronimpact gas chromatography-mass spectrometry was performed on a 5891A gas chromatograph connected with a 5971A quadrupole mass spectrometer (Hewlett-Packard Co., Palo Alto, CA). The isotopic ratio was determined by selected ion monitoring at m/z of 282 and 285. Calculations of apoB100 kinetic parameters were based on the tracer-to-tracee mass ratio (Cobelli et al., 1992) .
Measurements of Lipids and apoB100. Cholesterol and triglyceride levels were measured using commercially available enzymatic kits (Boehringer Mannheim GmbH, Mannheim, Germany) at three different sampling times. The apolipoprotein AI concentration in plasma was measured by immunonephelemetry (Behring, Rueil Malmaison, France) at the same sampling times. ApoB100 concentrations were obtained in lipoprotein fractions by combining selective precipitation and mass spectrometry (Beghin et al., 2000) . The percentage recovery of cholesterol, triglycerides, and apolipoprotein B100 after centrifugation was higher than 85%
Modeling. Kinetic analysis of tracer-to-tracee ratios was achieved using computer software for simulation, analysis and modeling (Bar- 
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at ASPET Journals on November 4, 2017 jpet.aspetjournals.org rett et al., 1998) . The model used (Fig. 1) is adapted from a minimal model previously developed for apoB100 metabolism in normolipidemic subjects (Maugeais et al., 2001 ), but taking into account heterogeneity in VLDL as reported in type-2 diabetics (Tilly-Kiesi et al., 1996) , e.g., large (VLDL1) and small VLDL (VLDL2), VLDL remnants (VLDLR), and shunt between VLDL and LDL. In this model, apoB100 enters into plasma through VLDL secretion and direct production of IDL and LDL. ApoB100 direct removal occurs from VLDL1 [k ( k(40,30) ]. The use of more complex models did not provide significant improvement in the fitting from the F test and Akaike information criterion (Pont et al., 1998) . A forcing function, corresponding to the time course of plasma leucine enrichment, was used to drive the appearance of leucine tracer into apoB100 of the different lipoprotein fractions (Maugeais et al., 2001) . For comparison between the three groups (controls and diabetics subjects before and after treatment) the VLDL1, VLDL2, and VLDLR data were presented as VLDL delipidation rate and VLDL fractional catabolic rate (FCR), which represents the sum of delipidation and direct removal rate. The VLDL delipidation rate was calculated as VLDL2 delipidation flux divided by total VLDL mass. The VLDL direct removal was calculated as flux of VLDL1, VLDL2, and VLDLR direct removal divided by total VLDL mass.
As all our patients are obese, pools of apoB100 in plasma or in VLDL, IDL, and LDL were calculated by multiplying the apoB100 concentration by 0.037 (l/kg), assuming a plasma volume of 3.7% of body weight (Dagher et al., 1965) . The apoB100 production rate in milligrams per kilogram per hour represents the product of FCR and pool size of apoB100 in lipoprotein fractions.
Statistical Analysis
Results are reported as the mean Ϯ standard deviation. The Mann-Whitney-test, performed with Statview F-4.5 (Abacus Concept, Berkeley, CA) was used. A two-tailed probability level of 0.05 or less was accepted as statistically significant.
Results
Lipoproteins, Lipids, and Apolipoproteins. Concentrations of lipids and apoB100 in plasma and in lipoprotein fractions are shown in Tables 1 and 2 for control subjects and diabetic patients before and after atorvastatin treatment. Patients before treatment compared with controls showed hypertriglyceridemia (340 Ϯ 167 mg/dl, P Ͻ 0.05) and hypercholesterolemia (269.7 Ϯ 31 mg/dl, P Ͻ 0.05). These diabetic patients showed higher total apoB100 concentration than controls (P Ͻ 0.005). This difference was explained by a higher concentration in the three studied lipoproteins. In VLDL, higher (P Ͻ 0.005) apoB100 content in diabetic patients was related to an increased content in both VLDL1 (P Ͻ 0.005) and VLDL2 (P Ͻ 0.005). No difference was observed in apolipoprotein AI between diabetic patients and controls.
Treatment with atorvastatin significantly decreased triglyceridemia (246.4 Ϯ 116.4 versus 340.0 Ϯ 167.0 mg/dl, P Ͻ 0.05) and cholesterolemia (189.3 Ϯ 49.4 versus 269.7 Ϯ 31.0 mg/dl, P Ͻ 0.05). Concentration of apoB100-VLDL decreased by 30% (P Ͻ 0.05). This decrease was significant in VLDL1 (P Ͻ 0.05) and VLDL2 (P Ͻ 0.05). Treatment also significantly decreased IDL and LDL apoB100 concentration, respectively, by 30% (P Ͻ 0.05) and 40% (P Ͻ 0.05). Routine biochemical and hematological examinations were unaffected by atorvastatin administration (not shown), with no change in the body mass index, fasting plasma glucose, HOMA, or hemoglobin A1c concentrations.
Lipoproteins Kinetics. Representative curves for a control (subject C1) and for a diabetic patient (subject D2) before and after atorvastatin treatment are shown in Fig. 2 . Model fitted lines and experimental points showed close agreement. Values of B100 masses in each compartment calculated with the model from steady state were in close agreement with chemically measured values (differences between predicted and measured values were of 5 to 20%, data not shown). Methods provided identified values Ϯ standard deviation as obtained by iterative least-squares fitting for individual kinetic parameters. Standards deviation were less than 30% for most of the parameters (data not shown). At baseline a dramatic increase of total apoB100 production was observed in type-2 diabetic patients compared with controls (240% of controls, P Ͻ 0.005) ( Table 3 ). This was related to a higher apoB100-VLDL production (P Ͻ 0.005), with no change for other lipoproteins. VLDL FCR was lower (67% of the controls but not significantly) related to decreased delipidation rate (one-third of the controls, P Ͻ 0.005). IDL FCR was also decreased (P Ͻ 0.005) related to a lower delipidation rate (P Ͻ 0.05). In contrast to low LDL apoB100 FCR (57% of the controls, P Ͻ 0.05), the diabetic patients had no consistent perturbations in LDL-apoB100 production compared with controls (increased in two subjects, with no change in two subjects, and decreased in three subjects).
Treatment with atorvastatin significantly reduced overall production of apoB100 by 20% (0.91 Ϯ 0.41 versus 1.17 Ϯ 0.59 mg/kg/h, P Ͻ 0.05) ( Table 3 ). This decrease was related to VLDL-apoB100 production (P Ͻ 0.05), with no significant change in direct production for IDL and LDL. The most dramatic change induced by atorvastatin treatment was the normalization of IDL and LDL FCR (2-fold increase compared with baseline, P Ͻ 0.05) with no change of VLDL FCR or delipidation rate. The increase of IDL FCR was related to significant increase of delipidation rate to LDL (P Ͻ 0.05).
Discussion
This study is the first kinetic analysis of effect of atorvastatin on apoB100 metabolism in type-2 diabetes. Analyses were performed using stable isotopes taking into account heterogeneity of VLDL and comparisons were made to matched controls. The model used in this study is consistent as shown by a low coefficient of variation for most of the individual parameters. The principal conclusion of this study is that in type-2 diabetes atorvastatin lowered triglyceridemia by lowering apoB100 VLDL production and cholesterolemia essentially by stimulating LDL uptake.
Effect of Diabetes on apoB100 Metabolism. Studied type-2 diabetic patients showed hypertriglyceridemia related to an increased VLDL concentration (both VLDL1 and VLDL2). This was linked to a higher VLDL production rate in all the patients and lower delipidation rate of VLDL resulting in a low total FCR of VLDL in most of the subjects. Previous kinetic studies have shown increased VLDL production rate in type-2 diabetes (Kissebah et al., 1982; Cummings et al., 1995) . In rat hepatocytes, insulin inhibits apoB100 secretion by stimulating degradation of newly synthesized apoB100 (Sparks and Sparks, 1990) . Then, hepatic VLDLapoB100 overproduction in type-2 diabetes could result from impaired action of insulin. In animal models, resistance to insulin action increased intracellular stability of nascent apoB100 and enhanced expression of microsomal triglyceride transfer protein, which facilitated the assembly and secretion of apoB100-containing lipoprotein particles (Taghibiglou et al., 2000) .
The observed decrease in VLDL delipidation rate compared with controls results in normal or lower (Kissebah et al., 1982 ) FCR of VLDL. The decrease of VLDL delipidation rate reported in type-2 diabetes (Taskinen et al., 1990 ) is related to insulin resistance (Eckel, 1989) . Another possible cause could be the physical changes of VLDL making these lipoproteins a poor substrate for LPL (lipoprotein lipase) (Saheki et al., 1993) .
Hypercholesterolemia was related to a high concentration of LDL in all the patients. This high concentration of LDL apoB100 was induced by a low FCR of LDL in most of the patients compared with controls. This decrease of LDL FCR already reported could be explained by an insulin stimulating effect on LDL receptor activity (Taskinen et al., 1990 ) and a glycosylation of LDL particles that can alter binding to these receptors (Hiramatsu et al., 1985) .
In type-2 diabetic patients, compared with controls, VLDL was less channeled toward conversion into LDL than direct removal (data not shown), as previously reported in other studies Taskinen et al., 1990) . This is related to the decreased VLDL delipidation rate discussed above. Such a situation could explain the lack of high concentrations of LDL frequently observed in spite of low LDL catabolism. Both perturbations with contradictory effects on LDL concentrations could explain the inconsistent increase of LDL amount reported in type-2 diabetes. Fig. 2 . Time course of enrichment of plasma leucine (Ϫ) and apolipoprotein B100 in representative control (subject C1; A) and representative diabetic (subject D2) before (B) and after atorvastatin treatment (C) for VLDL1 (Ⅺ), VLDL2 (✳), IDL (E) and LDL (ϩ).
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Atorvastatin decreased the production rate of VLDL apoB100 in spite of insulin resistance. The production rate of VLDL is controlled by liver cholesterol availability and particularly from de novo synthesis through possible effect on translocation, intracellular apoB100 degradation, ACAT activity, and microsomal triglyceride transfer protein activity . Statins through their effects on HMG-CoA reductase inhibition decrease the intrahepatic free cholesterol concentration. It has been previously reported in cellular models that atorvastatin, but not simvastatin, decreased the production of VLDL apoB100 . This effect could be only observed for the most potent statins because it was shown in animals that the magnitude of decrease in hepatic VLDL apoB100 secretion is determined by the extent of HMG-CoA reductase inhibition (Burnett et al., 1999) . The mechanisms possibly involved a defect of translocation of apoB100 into the lumen of the endoplasmic reticulum, increasing by this way the amount of apoB100 degraded within the cell (Mohammadi et al., 1998) . Atorvastatin could decrease cholesterol synthesis and availability of cholesterol and cholesterol ester for the normal assembly of apoB100 containing lipoprotein particles. Using lovastatin (Arad et al., 1990; Cuchel et al., 1997) and pravastatin (Vega et al., 1990) , it was shown a decrease in VLDL production. Nevertheless, it has recently been reported no atorvastatin effect on VLDL production rate in moderate combined hyperlipidemic subjects (Forster et al., 2002) and insulin resistant patients with no diabetes and less marked VLDL overproduction (Chan et al., 2002) . These apparently conflicting results could come from studying patients with different metabolic profiles and specially different level of VLDL production (Illingworth, 1991; Aguilar-Salinas et al., 1998) .
Opposite results were found for effect of treatment on delipidation rate of IDL and VLDL. Delipidation process of IDL is catalyzed by hepatic lipase (Olivecrona and Olivecrona, 1995) and was normalized by treatment. As discussed above, activity of lipoprotein lipase appears to be modulated by insulin resistance activity but hepatic lipase could be independent of insulin action and essentially modulated by changes of IDL composition. Whatever the mechanisms of the contradictory effects of atorvastatin on delipidation process, our results suggest that delipidation rates of VLDL and IDL are not regulated by the similar pathways, as previously reported (Peinado-Onsurbe et al., 1992) .
The main change induced by the treatment concerned LDL. Treatment with a statin is reported to decrease LDL production rate and/or to increase LDL catabolism. For example, in combined hyperlipidemia (Cuchel et al., 1997) , lovastatin decreased LDL production rate without change of catabolism. In another form of familial combined hyperlipidemia (Aguilar-Salinas et al., 1997), pravastatin increased LDL FCR with no change of production rate. The same result was reported in normolipidemic volunteers during simvastatin treatment (Malmendier et al., 1989) . This inconsistency could result from the dose used (and potency of the statin used) and from the studied pathological situation (AguilarSalinas et al., 1998) . In the present study, atorvastatin normalized LDL concentration by normalizing FCR through stimulating LDL receptor activity, as previously demonstrated with simvastatin (Malmendier et al., 1989 ).
In conclusion, our kinetic data demonstrated the various effects of atorvastatin on dyslipidemia in type-2 diabetes and underlined the usefulness of this treatment even in case of increase of triglycerides and moderate increase of LDL cholesterol.
